Xeris Biopharma Holdings (XERS) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to $0.0.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) rose 10317.84% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.1, marking a year-over-year increase of 7727.27%. This contributed to the annual value of -$0.37 for FY2024, which is 1697.52% up from last year.
- As of Q3 2025, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) stood at $0.0, which was up 10317.84% from -$0.01 recorded in Q2 2025.
- Xeris Biopharma Holdings' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.0 during Q3 2025, with a 5-year trough of -$0.44 in Q4 2021.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.16, with a median of -$0.12 in 2023.
- As far as peak fluctuations go, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) tumbled by 2222.22% in 2024, and later skyrocketed by 10317.84% in 2025.
- Over the past 5 years, Xeris Biopharma Holdings' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.44 in 2021, then soared by 77.27% to -$0.1 in 2022, then grew by 10.0% to -$0.09 in 2023, then skyrocketed by 61.29% to -$0.03 in 2024, then surged by 110.04% to $0.0 in 2025.
- Its EPS (Weighted Average and Diluted) was $0.0 in Q3 2025, compared to -$0.01 in Q2 2025 and -$0.06 in Q1 2025.